Literature DB >> 29348071

A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design.

Sundus Akhter1, Bjarte Aarmo Lund2, Aya Ismael1, Manuel Langer1, Johan Isaksson1, Tony Christopeit2, Hanna-Kirsti S Leiros3, Annette Bayer4.   

Abstract

β-Lactam antibiotics are of utmost importance when treating bacterial infections in the medical community. However, currently their utility is threatened by the emergence and spread of β-lactam resistance. The most prevalent resistance mechanism to β-lactam antibiotics is expression of β-lactamase enzymes. One way to overcome resistance caused by β-lactamases, is the development of β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48 for useful enzyme-inhibitor interactions. In the presented study, a focused fragment library containing 49 3-substituted benzoic acid derivatives were synthesised and biochemically characterized. Based on crystallographic data from 33 fragment-enzyme complexes, the fragments could be classified into R1 or R2 binders by their overall binding conformation in relation to the binding of the R1 and R2 side groups of imipenem. Moreover, binding interactions attractive for future inhibitor design were found and their usefulness explored by the rational design and evaluation of merged inhibitors from orthogonally binding fragments. The best inhibitors among the resulting 3,5-disubstituted benzoic acids showed inhibitory potential in the low micromolar range (IC50 = 2.9 μM). For these inhibitors, the complex X-ray structures revealed non-covalent binding to Arg250, Arg214 and Tyr211 in the active site and the interactions observed with the mono-substituted fragments were also identified in the merged structures.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Benzoic acid derivatives; Crystal structure; Fragments; Inhibition properties; Serine-β-lactamase inhibitors; Structure-guided drug design

Mesh:

Substances:

Year:  2017        PMID: 29348071     DOI: 10.1016/j.ejmech.2017.12.085

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  17 in total

1.  Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.

Authors:  Orville A Pemberton; Priyadarshini Jaishankar; Afroza Akhtar; Jessie L Adams; Lindsey N Shaw; Adam R Renslo; Yu Chen
Journal:  J Med Chem       Date:  2019-09-13       Impact factor: 7.446

2.  Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.

Authors:  Clyde A Smith; Nichole K Stewart; Marta Toth; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors.

Authors:  Yuejuan Zhang; Cheng Chen; Bin Cheng; Lei Gao; Chuan Qin; Lixia Zhang; Xu Zhang; Jun Wang; Yi Wan
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

Review 4.  β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates.

Authors:  Montserrat Mora-Ochomogo; Christopher T Lohans
Journal:  RSC Med Chem       Date:  2021-08-04

5.  Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries.

Authors:  Doris Mia Taylor; Justin Anglin; Suhyeorn Park; Melek N Ucisik; John C Faver; Nicholas Simmons; Zhuang Jin; Murugesan Palaniappan; Pranavanand Nyshadham; Feng Li; James Campbell; Liya Hu; Banumathi Sankaran; B V Venkataram Prasad; Hongbing Huang; Martin M Matzuk; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2020-03-25       Impact factor: 5.084

Review 6.  Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Authors:  Adam Stewart; Patrick Harris; Andrew Henderson; David Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

7.  Mechanistic Basis of OXA-48-like β-Lactamases' Hydrolysis of Carbapenems.

Authors:  Vlatko Stojanoski; Liya Hu; Banumathi Sankaran; Feng Wang; Peng Tao; B V Venkataram Prasad; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2021-01-25       Impact factor: 5.084

8.  C6 Hydroxymethyl-Substituted Carbapenem MA-1-206 Inhibits the Major Acinetobacter baumannii Carbapenemase OXA-23 by Impeding Deacylation.

Authors:  Nichole K Stewart; Marta Toth; Maha A Alqurafi; Weirui Chai; Thu Q Nguyen; Pojun Quan; Mijoon Lee; John D Buynak; Clyde A Smith; Sergei B Vakulenko
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

9.  Structural insights into the enhanced carbapenemase efficiency of OXA-655 compared to OXA-10.

Authors:  Hanna-Kirsti S Leiros; Ane Molden Thomassen; Ørjan Samuelsen; Carl-Fredrik Flach; Stathis D Kotsakis; D G Joakim Larsson
Journal:  FEBS Open Bio       Date:  2020-08-08       Impact factor: 2.693

10.  OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.

Authors:  Christopher Fröhlich; Vidar Sørum; Ane Molden Thomassen; Pål Jarle Johnsen; Hanna-Kirsti S Leiros; Ørjan Samuelsen
Journal:  mSphere       Date:  2019-03-27       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.